Table 3. Analysis of response and survival of patients with gastric cancer receiving capecitabine plus paclitaxel (cohort 1) or cisplatin (cohort 2).
| Outcome | Cohort 1 (n=36) |
Cohort 2 (n=21) |
Total (n=57) |
||||
|---|---|---|---|---|---|---|---|
| No. of patients % | No. of patients % | No. of patients % | |||||
| Response | |||||||
| Partial response | 17 | 47.2 | 7 | 33.3 | 24 | 42.1 | |
| Stable disease | 10 | 27.8 | 7 | 33.3 | 17 | 29.8 | |
| Progression disease | 9 | 25.0 | 7 | 33.3 | 16 | 28.1 | |
| Overall response rate | 15 | 47.2 | 7 | 33.3 | 22 | 42.1 | |
| Median PFS, months | 4.5 | 3.9 | 4.1 | ||||
| 95% CI | 1.5-7.5 | 1.9-6.0 | 2.2-6.0 | ||||
| Median OS, months | 8.5 | 9.2 | 9.2 | ||||
| 95% CI | 6.3-10.7 | 4.2-14.2 | 7.1-11.3 | ||||